Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of coadministration of dengue tetravalent vaccine and 9-valent HPV vaccine in children and adolescents
2022-003339-24Phase 3
- Sponsor
- Takeda
- Start
- Dec 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dengue tetravalent vaccine, live, attenuated and recombinant human papillomavirus 9-valent vaccine in dengue fever and human papillomavirus infection (2 arms), sponsored by Takeda. Primary endpoint: Geometric mean titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
02
Drugs
dengue tetravalent vaccine, live, attenuatedrecombinant human papillomavirus 9-valent vaccine
03
Conditions
dengue feverhuman papillomavirus infection
Beyond the preview
Go deeper on 2022-003339-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003339-24.